SG11202113125QA - Peptides - Google Patents

Peptides

Info

Publication number
SG11202113125QA
SG11202113125QA SG11202113125QA SG11202113125QA SG11202113125QA SG 11202113125Q A SG11202113125Q A SG 11202113125QA SG 11202113125Q A SG11202113125Q A SG 11202113125QA SG 11202113125Q A SG11202113125Q A SG 11202113125QA SG 11202113125Q A SG11202113125Q A SG 11202113125QA
Authority
SG
Singapore
Prior art keywords
peptides
Prior art date
Application number
SG11202113125QA
Other languages
English (en)
Inventor
Jon Amund Eriksen
Original Assignee
Hubro Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubro Therapeutics As filed Critical Hubro Therapeutics As
Publication of SG11202113125QA publication Critical patent/SG11202113125QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202113125QA 2019-05-29 2020-05-28 Peptides SG11202113125QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19177444 2019-05-29
PCT/EP2020/064893 WO2020239937A1 (en) 2019-05-29 2020-05-28 Peptides

Publications (1)

Publication Number Publication Date
SG11202113125QA true SG11202113125QA (en) 2021-12-30

Family

ID=66677029

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113125QA SG11202113125QA (en) 2019-05-29 2020-05-28 Peptides

Country Status (21)

Country Link
US (1) US20220213170A1 (es)
EP (2) EP4276463A3 (es)
JP (1) JP2022535784A (es)
KR (1) KR20220012938A (es)
CN (1) CN113891723A (es)
AU (1) AU2020281912A1 (es)
BR (1) BR112021023957A2 (es)
CA (1) CA3141951A1 (es)
CO (1) CO2021017664A2 (es)
DK (1) DK3840767T3 (es)
ES (1) ES2970223T3 (es)
FI (1) FI3840767T3 (es)
HR (1) HRP20240017T1 (es)
IL (1) IL288412A (es)
LT (1) LT3840767T (es)
MX (1) MX2021014497A (es)
PL (1) PL3840767T3 (es)
PT (1) PT3840767T (es)
SG (1) SG11202113125QA (es)
SI (1) SI3840767T1 (es)
WO (1) WO2020239937A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157335A2 (en) 2020-05-28 2023-04-05 Hubro Therapeutics AS A peptide cocktail
EP4367260A1 (en) 2021-07-09 2024-05-15 Hubro Therapeutics AS A primer
EP4223782A1 (en) * 2022-02-07 2023-08-09 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Novel t cell receptors and immune therapy using the same for the treatment of cancer
WO2024052542A2 (en) 2022-09-09 2024-03-14 Hubro Therapeutics As A peptide cocktail

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
ES2331252T3 (es) * 2005-09-20 2009-12-28 Peter Jon Nelson Inhibidor tisular de metaloproteinasas (timp) unido a anclajes de glucosilfosfatidilinositol (gpi) para el tratamiento del cancer.
WO2011125334A1 (en) * 2010-04-09 2011-10-13 Oncotherapy Science, Inc. Cdca5 peptides and vaccines including the same
WO2011146121A1 (en) * 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
JP2020522477A (ja) * 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 汎用癌ワクチンおよびそれを製造ならびに使用する方法

Also Published As

Publication number Publication date
JP2022535784A (ja) 2022-08-10
HRP20240017T1 (hr) 2024-04-26
FI3840767T3 (fi) 2024-01-31
CN113891723A (zh) 2022-01-04
PL3840767T3 (pl) 2024-03-04
SI3840767T1 (sl) 2024-04-30
MX2021014497A (es) 2022-02-11
CO2021017664A2 (es) 2022-01-17
US20220213170A1 (en) 2022-07-07
BR112021023957A2 (pt) 2022-02-01
PT3840767T (pt) 2024-01-29
EP4276463A2 (en) 2023-11-15
EP4276463A3 (en) 2024-01-10
DK3840767T3 (da) 2024-02-12
CA3141951A1 (en) 2020-12-03
ES2970223T3 (es) 2024-05-27
EP3840767B1 (en) 2023-11-15
LT3840767T (lt) 2024-02-26
EP3840767A1 (en) 2021-06-30
KR20220012938A (ko) 2022-02-04
AU2020281912A1 (en) 2022-01-20
IL288412A (en) 2022-01-01
WO2020239937A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
IL275298A (en) Mitochondria-targeted peptides
IL288412A (en) peptides
IL280678A (en) Cell-penetrating peptides
IL289122A (en) polypeptides
IL289119A (en) polypeptides
IL285144A (en) Medicinal peptides
GB201900443D0 (en) Cell-penetrating peptides
IL284006A (en) Mitochondria-targeted peptides
IL290520A (en) Medicinal peptides
GB201700557D0 (en) Novel peptides
GB201810052D0 (en) Polypeptide
IL290019A (en) Peptides to regulate melanocytes
GB201906982D0 (en) Peptides
GB201902850D0 (en) Antimicroial peptides
GB201918693D0 (en) Peptide
GB201912632D0 (en) Peptide
GB201807863D0 (en) Peptides
GB201806181D0 (en) Peptides
GB201805809D0 (en) Peptides
GB201805807D0 (en) Peptides
GB201805801D0 (en) Peptides
GB202113858D0 (en) Peptides
GB202110693D0 (en) Peptides
GB201814440D0 (en) Peptide
GB201803074D0 (en) Peptide